

To Study Level of Serum Cortisol and Prolactin in Diabetic Retinopathy

Khan S¹, Sabah S², Waris A³, Siddiqi S.S⁴

1. Junior resident, MS Ophthalmology, Institute of Ophthalmology, JNMCH, AMU, Aligarh.

2. Junior resident, MS Ophthalmology, Institute of Ophthalmology, JNMCH, AMU, Aligarh.

3. Assistant Professor, Institute of Ophthalmology, VR Surgeon, MS Ophthalmology, FICS (USA) FICO (UK), FRCS (Glasg), FRCS (Edin) JNMCH, AMU, Aligarh

4. Associate Professor and Director, Rajiv Gandhi Centre for Diabetes and Endocrinology, JNMCH, AMU, Aligarh.

Corresponding Author: Waris A

Abstract: Diabetic retinopathy refers to retinal changes seen in patients with diabetes mellitus. Degree of cortisol secretion is related to the presence and number of diabetic complications (Diabetes care 30:83-88, 2007). The hormone prolactin is proteolytically processed to vasoinhibins, a family of peptides that inhibit the excessive retinal vasopermeability related to diabetic retinopathy after its intraocular conversion to vasoinhibins (Diabetes 59:3192-3197, 2010). The Research aims to find out the effect of serum cortisol and prolactin levels in patients of diabetic retinopathy.

Keywords: Diabetic Retinopathy, Cortisol, Prolactin, Microvascular complications.

Date of Submission: 29-01-2019

Date of acceptance: 14-02-2019

I. Introduction

Diabetic retinopathy (DR) is a leading cause of vision loss globally. Diabetic retinopathy refers to retinal changes seen in patients with diabetes mellitus. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have sign of DR and of these, further one third of DR is vision-threatening DR, including diabetic macular edema (DME). With increase in life expectancy the incidence of diabetic retinopathy [DR] has increased. The identification of established modifiable risk factors for DR such as hyperglycemia and hypertension has provided the basis for risk factor control in preventing onset and progression of diabetic retinopathy (Lee R et al, 2015).

Diabetic retinopathy has many risk factors which aggravate the progression of the disease. Of these there are well known risk factors and some less studied ones. Cortisol which is a steroid hormone, in the glucocorticoid class of hormones. It is released in response to stress and low glucose concentrations. It functions to increase blood sugar through gluconeogenesis, to suppress the immune system, and to aid in the metabolism of fat, protein, and carbohydrates. It also decreases bone formation^[1]. Increase in cortisol levels lead to increase in blood sugar levels causing worsening of diabetic control. Due to this reason increased cortisol levels lead to increase in all diabetic related vasculopathy including retinopathy.

CORTISOL LEVEL RANGE:

20 µg/dL-5µg/dL

The secretory rates of cortisol are high in the morning, but low in the late evening. The plasma cortisol level ranges between a high of about 20 µg/dL in the morning to a low of about 5µg/dL around midnight^[2]. Therefore the measurements of blood cortisol levels of all patients are to be made at a similar time to minimize error due to diurnal variation.

Prolactin which is a protein hormone stimulates the mammary glands for milk production and so plays important role in lactation^[1]. Serum prolactin derived vasoinhibins which are proteins obtained after proteolytic cleavage of prolactin have been shown to be protective in diabetic retinopathy. The direct role of prolactin levels in diabetic retinopathy however is not clear and a matter of further study. So we will be studying both of them and their relation with each other.

PROLACTIN LEVEL RANGE:

For Women= 10µg/dL – 25µg/dL

For Men= 10µg/dL-20µg/dL [3]

MATERIAL AND METHOD

We are conducting a Cross sectional analytical study design at JN Medical College A.M.U. Aligarh, after taking ethical clearance from institutional Ethical Committee of the college. In this study we are trying to compare the levels of Serum prolactin and Serum cortisol in patients with diabetic retinopathy with diabetic patients without diabetic retinopathy. We will also try to find out any relationship between Serum cortisol and Serum prolactin levels in both groups.

Brief clinical history will be taken and clinical examination including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, fundus photograph and collection of blood sample.

II. Discussion

Cortisol

Bhatia RP and Adarsh Singh^[4] undertook a study in which Plasma cortisol levels and its metabolite-17-hydroxycorticosteroids were evaluated from the urine of 53 patients. These 53 patients had early and late stages of diabetic retinopathy. Values were compared with 30 cases of a control group. Plasma cortisol was found to be raised significantly in early as well as in advanced stages of retinopathy, while 17-hydroxycorticosteroid was significantly raised in earlier stages of diabetic retinopathy only. The findings suggest that increased plasma cortisol levels may take some part in the production of diabetic retinopathy.

Roy MS et al^[5] conducted a study in which they measured urinary free cortisol output in diabetic patients. They compared a group of 35 insulin dependent diabetic outpatients with a group of 32 normal controls for 24 hr urinary free cortisol. They found out that diabetic patients had significantly greater 24 hr UFC outputs than control. There were trends for patients for patients with either diabetic retinopathy or diabetic cardiovascular complications to have higher 24 hr UFC outputs than patients without these complications.

Iacopochiodini et al^[6] conducted a study in which cortisol level relationship with chronic complications of diabetes were studied. They enrolled 294 type 2 diabetic patients to evaluate the presence of subclinical hypercortisolism in diabetes, biochemical parameters of HPA axis secretion and the presence of diabetic complications. In all subjects the following determinants were performed: serum cortisol levels at 12 p.m. [F 24], 24 hr urinary free cortisol and plasma ACTH. They found out that parameters of HPA were not associated with the presence of diabetic complications whereas F 24 was significantly related to retinopathy [P=0.010] and neuropathy [P=0.039].

In type 2 diabetes subjects, hypothalamic – pituitary adrenal activity is enhanced in patients with diabetic complications and the degree of cortisol secretion is related to the presence and number of diabetic complications. (Diabetes care 30: 83-88, 2007)

In patients with type 2 diabetes, glucocorticoid secretion has been suggested to be a possible link between insulin resistance and the features of the metabolic syndrome (hypertension, obesity, coronary heart disease, hyperlipidemia and type 2 diabetes)⁽⁷⁻¹⁰⁾

Glucocorticoid excess has been demonstrated to lead to diabetes or to worsen metabolic control⁽¹¹⁻¹³⁾.

PROLACTIN

Pan H et al^[14] conducted a study in which he examined the role of 16 kDa N-terminal fragment of human prolactin [16K hPRL] in the inhibition of abnormal retinal neovascularisation. Intravitreal injections of 16K hPRL inhibited neovascularisation in the mouse model of oxygen induced retinopathy, suggesting a role for 16K hPRL in the treatment of proliferative retinopathies.

Aranda J et al^[15] also conducted a similar study in rats and concluded that Prolactin is cleaved to antiangiogenic 16K-PRL by retinal tissue and that these molecules play a key role in preventing angiogenesis in the healthy retina.

Edith Arnold et al^[16] conducted a study in which serum prolactin was evaluated in 40 nondiabetic and 181 diabetic men at various stages of Diabetic retinopathy. They found out that serum prolactin levels were higher in diabetic patients with no retinopathy than in those with proliferative diabetic retinopathy. All diabetic patients showed higher levels of PRL than the control subjects [P<0.005]. However, patients with PDR had a reduced concentration of PRL [P<0.05] compared with diabetic patients without retinopathy. The pattern of circulating PRL levels did not depend on the type of diabetes or on other systemic complications associated with diabetes [hypertension and nephropathy].

Triebel J et al^[17] conducted a study to investigate prolactin related vasoinhibin in sera from patients with diabetic retinopathy. They performed a case control study and semi quantitatively determined Prolactin related vasoinhibin [PRL-V] in serum samples from 48 male subjects. The case group consisted of 21 patients with diabetes mellitus and proliferative or non-proliferative diabetic retinopathy. The control group consisted of 27 healthy subjects with no history of diabetes mellitus. They found out that the case group had significantly lower PRL-V serum concentrations than the control group [P=0.041]. There was no significant difference between patients with proliferative and those with non proliferative diabetic retinopathy

BonakdaranShokoofeh et al^[18] in a study enrolled 212 type 2 diabetics. The case group consisted of 70 patients with type 2 diabetes mellitus who suffered either proliferative [n=24] or non-proliferative [n=46] diabetic retinopathy. The control group consisted of 142 type 2 diabetics without retinopathy. The serum 23KD prolactin levels were estimated. They found out that there was no difference in serum 23 KD prolactin level between retinopathic and non-retinopathic diabetics. The association between PRL and diabetic retinopathy has always been a matter of controversy.

The hormone prolactin is proteolytically processed to vasoinhibins, a family of peptides that inhibit the excessive retinal vasopermeability related to diabetic retinopathy after its intraocular conversion to vasoinhibins. Inducing hyperprolactinemia may represent a novel therapy against diabetic retinopathy. (Diabetes 59: 3192 - 3197, 2010).

Vasoinhibins are a family of antiangiogenic prolactin fragments that inhibit ischaemia induced retinal angiogenesis and prevent excessive retinal vasopermeability associated with diabetes^(19,20). Prolactin is an important systemic inhibitor of diabetes induced retinal hypervasopermeability after its intraocular conversion to vasoinhibins, which act directly on endothelial cells to block blood vessel growth, dilatation and permeability and to promote apoptosis mediated vascular regression.⁽²⁰⁾

Take home Message

Diabetic retinopathy has many risk factors which aggravate the progression of disease of these there are well known risk factors and some less studied ones. Cortisol serum levels have been shown to cause increase in diabetic retinopathy complications and serum prolactin levels may be protective diabetic retinopathy. Vasoinhibins derived from prolactin may provide future beneficial role in therapy for diabetic retinopathy.

References

- [1]. Source= Adopted from Ganong's Review of Medical Physiology, 24th edition.
- [2]. Source=Adopted from Ganong ,WF,Review of Medical Physiology,22nd edition.
- [3]. Source=Adopted from Harisson's book of internal medicine, 19th edition.
- [4]. BhatiaRP,Adarsh Singh RH:Cortisol in diabetic retinopathy. *AnnOphthalmol* 15:128-130,1983
- [5]. RoyMS,RoyA,Brown S:Increased urinary free cortisol outputs in diabetic patients. *J Diabetes complications* 12:24-27,1998
- [6]. Iacopo Chiodini ,Guido Adda,AlfredoScintillani,FrancescaColetti,ValentinaMorelli,Sergio Di Limbo,PaolaEpaminonda,BendettaMasserini,PaoloBeck,EmanuellaOrsi,BrunoAmbrosi,MauraArosio.Cortisol Secretion in patients with type 2 Diabetes:relationship with chronic complications. *DiabetesCare*, Volume 30, Number 1, January 2007
- [7]. Andrews RC, WALKER BR:Glucocorticoids and insulin resistance old hormones,new targets *ClinSci[lon]d*96:513-523,1999
- [8]. Bjontorp P,HolmG,Rosmond R:Hypothalamic arousal,insulin resistance and type 2 diabetes mellitus. *Diabet Med* 16:373-381,1999
- [9]. Philips DI,BarkerDJ,FallCH,SecklJR,WhorlwoodCB,WoodPJ,WalkerBR:Elevated plasma cortisol concentrations :a link between low birth weight and the insulin resistance syndrome?*JClinEndocrinolMetab* 83:757-760,1998
- [10]. AndrewsRC,HerlihyO,LivingstoneDE,AndrewR,WalkerBR:Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. *JClinEndocrinolMetab* 87:5587-5593,2002
- [11]. Arnaldi ,AngeliA,AtkinsonAB,BertagnaX,CavagniniF,ChrousosGP,FavaGA,FindlingJW,GaillardRC,GrossmanAB,KolaB,Lacroix A:Diagnosis and complications of Cushing's Syndrome:a consensus statement. *JClinEndocrinolMetab* 88:5593-5602,2003
- [12]. TauchmanovaL,RossiR,BiondiB,Pulcrano M:*J ClinEndocrinolMetab* 87:4869-4871,2002
- [13]. Chiodini I,TorlontanoM,ScillitaniA,ArosioM,BacciS,Di limbo S,AmbrosiB,Adda G:Association of sub-clinical hypercortisolism with type 2 diabetes mellitus :a case control study in hospitalized patients. *Eur J Endocrinol* 153:837-844,2005
- [14]. Pan H,NguyenNq,YoshidaH,benzteinF,ShawLC,Renteir-DelrueF,MartialJA,WeinerR,StrumannI,GrantMB.Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen induced retinopathy in mice. *InvestOphthal Vis Sci* 2004;45:2413-2419
- [15]. Aranda J,RiveraJC,JeziorskiMC,Riego -EscovarJ,NavaG,Lopez-Barrera F,Quiroz-Mercado H,BergerP,Martinez de la EscaraG,Clapp C. Prolactins are natural inhibitors of angiogenesis in the retina. *InvestOphthalmol Vis Sci* 2005;46:2947-2953
- [16]. Edith Arnold, JoseC, Rivera, Stephanie Thebault, Daniel Moreno-Paramo, Hugo Quiroz-Mercado, Andres Quintanar-Stephano, Nadine Binart, Gonzalo Martinez de la Escalera, and Carmen Clapp. High levels of serum prolactin protect against Diabetic Retinopathy by increasing Ocular Vasoinhibins. *Diabetes*, Vol 59, December 2010
- [17]. Triebel J,HuefnerM,RamadoriG. Investigation of prolactin related vasoinhibin in sera from patients with diabetic retinopathy. *Eur J Endocrinol* 2009;161:345-353
- [18]. BonakdaranShokoofeh,ShoebiNasser,MojtabaAbrishami and RokniHaleh.Serum prolactin level and diabetic retinopathy in type 2 diabetes. *J Diabetes Metab* 2012.
- [19]. Clapp C,ThebaultS,JeziorskiMC,Martinez De La EscaleraG.Peptide hormone regulation of angiogenesis. *Physiol Rev* 2009;89:1177-1215
- [20]. Garcia C,ArandaJ,ArnoldE,ThebaultS,MacotelaY,LopezcasillasF,MendozaV,ClappC.Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A dependent eNOS inactivation. *JClin Invest* 2008;118:2291-22300.

Waris A. "To Study Level of Serum Cortisol and Prolactin in Diabetic Retinopathy." *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, vol. 18, no. 2, 2019, pp 31-33.